The FDA granted Crispr Therapeutics (CRSP) orphan status for its treatment of follicular lymphoma.Don't Miss Our End of Quarter Offers: ...

Variant, a company dedicated to developing innovative treatments for orphan inherited eye diseases, and the Rare Ocular Diseases Center at the University ofCampania Luigi Vanvitelli ...

Bain Capital’s Life Sciences team led the funding round, with contributions from new investor Wellington Management.

AscellaHealth has introduced its latest Specialty & Rare Pipeline Digest™, a quarterly publication designed to provide ...

The $150 million will also go toward Atsena’s preclinical pipeline and expand the use of the biotech’s spreading AAV.SPR ...

Here is our list of the 11 Best Gene Therapy Stocks to Buy According to Analysts.

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

The original Gene line-up have reunited and announced their first live show in over 20 years. Read NME‘s interview with frontman Martin Rossiter below, where he discusses what to expect from the ...

“Orphan drug designation points to the need for ... Rhythm’s headquarters is in Boston, MA. genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).

Number of orphan wells in Alberta will soon double as controversial oilpatch bankruptcy settled 'A lost opportunity': Alberta gives back $137M to Ottawa in unspent funds to clean up inactive wells ...